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by decrease in other resources: € 1.4 million (total incremental budget) in the first year 
to € 3.7 million in the third year. ConClusions: The use of omalizumab to treat CSU 
with inadequate response to H1-antihistamines increases drug and drug-related costs, 
but this is partially offset by reduced disease-related costs in omalizumab recipients.
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introduCtion: Superiority of secukinumab, reported in two head to head (H2H) 
trials, provided new horizons to stablish standard of efficacy (clear skin or at least 
PASI 90) for biologic treatments (Bx) for patients with moderate-severe psoriasis. 
The budget impact of new Bx might preclude its use, preventing that patients can 
have objeCtives: To compare the cost-efficacy cost of Bx for moderate-severe psoria-
sis Methods: We built an average cost-efficacy model represented by a decision tree 
for a time horizon 2 years. Efficacy was measured as the proportion of patients achiev-
ing at least PASI 90. Patients considered non-responders at week 10-16 (as per SmPC 
recommendations) were switched to another Bx (consecutive treatment). Efficacy was 
drawn from published clinical trials (CT). For secukinumab and ustekinumab, efficacy 
data came from CLEAR study (H2H study comparing efficacy of both Bx). Highest 
efficacy according CT’s (week 24), was considered constant along the study period. 
Only pharmacologic costs were included in the analysis. Induction phase costs for 
the second Bx were ascribed to first Bx. Number Needed to Treat (NNT) and cost per 
patient achieving at least PASI 90, were calculated. results: Along 2 years, secuki-
numab monotherapy had the lowest NNT to achieve clear skin (NNT 1.39), followed 
by ustekinumab (2.44), infliximab (2.95), adalimumab (3.47) and etanercept (12.7). Out 
of the eleven most cost-efficacy consecutive treatments, secukinumab was present 
in 9, mainly as the first line Bx. ConClusions: Secukinumab had the lowest NNT to 
achieve at least PASI 90, with lower cost in the majority of alternatives analyzed. New 
standards of efficacy (cleasr skin or ar least PASI 90) are of paramount importance to 
achieve clear skin and better quality of life for patients. Economic analyses are also 
key for health care systems sustainability.
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objeCtives: Knowing the economic burden of pneumococcal infections on health-
care system is important for disease control and prevention. We aimed to esti-
mate the economic burden of pneumococcal infections in children < 5 years old in 
Turkey. Methods: Electronic medical records of children diagnosed with pneumo-
nia, meningitis, and acute otitis media (AOM) between January 2013 and April 2014 
were retrospectively evaluated. Children developed pneumonia 48 hours after hospi-
talization or hospitalized for ≥ 2 days in the last 90 days were excluded. Direct costs 
for inpatients (pneumonia and meningitis) included costs of healthcare services 
(hospitalization, visit, consultation, laboratory, radiology), drugs, and medical con-
sumables. Direct costs for outpatients (AOM) included hospital visit and prescribed 
drug costs. Indirect costs for all patients included parents’ productivity loss cost 
and their travel expenses to hospital. Costs were expressed as median (minimum-
maximum). results: Data of 131 children with meningitis (n= 10), pneumonia 
(n= 53), and AOM (n= 68) were analyzed. While the direct costs for meningitis, pneu-
monia, and AOM were € 3,346.38 (€ 591.54-€ 42,940.02), € 480.66 (€ 84.46-€ 18,627.56), 
and € 335.89 (€ 57.07-€ 2,765.58), respectively, their indirect costs were € 851.97 
(€ 415.55-€ 8,319.34), € 335.89 (€ 57.07-€ 2,765.58), and € 96.91 (€ 96.91-€ 310,406.23), 
respectively. The total cost was € 4,080.58 (€ 1007.1-€ 50,721.44) for meningitis, € 838.84 
(€ 141.53-€ 21,393.14) for pneumonia, and € 114.49 (€ 112.56-€ 310,438.64) for AOM. The 
economic burden will be € 9,258,836.02 for meningitis, € 190,317,696.88 for pneumo-
nia, and € 286,225,000 for AOM when the total costs per patient are adjusted to the 
annual average number of patients with meningitis, pneumonia, and AOM was 
2269; 226,882; and 2,500,000, respectively, in Turkey. Accordingly, the total economic 
burden of pneumococcal infections, excluding bacteremia, will be € 485,801,532.9 
in Turkey. ConClusions: Pneumococcal infections pose a significant burden on 
healthcare system due to its high direct and indirect costs. Thus, preventive actions, 
mainly vaccination, should be conducted regularly.
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objeCtives: dental implantation significantly improves the quality of patients’ 
life. However, it is an expensive treatment. We conducted our research to study 
the best price-quality relationship for dental implants made of different materials: 
titanium, zirconia and sandblasted and acid etched titanium implants. The objective 
of the present study was to analyze and compare prices for first stage implanta-
tion depending on the material of dental implant in ten private dental clinics in 
Ukraine. Methods: We compared and analyzed the costs of first stage of dental 
implantation which was conducted in 10 private dental clinics in Ukraine during the 
period of 6 month (01 December 2014 - 31 May 2015). For that purpose we selected 
five leading manufacturers which produce dental implants. Prices for the tech-
nologies and materials were set by the Administration of Dental clinic. Statistical 
analysis of the costs was performed by a computer program x7 2009. results: The 
prices for implantation in ten private dental clinics were used for the comparative 
cost calculation of technologies with five different implants: one zirconia, one tita-
nium and three sandblasted and acid etched titanium implants. According to our 
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objeCtives: Acne vulgaris is one of the most common skin conditions, affecting 
primarily the adolescents. This disorder is characterized by an abnormal function-
ing of the pilosebaceous follicle causing different types of lesions. The objectives 
of the present study were to determine the prevalence of acne in adolescents in 
Europe and evaluate the impact of environmental and lifestyle factors on this con-
dition. Methods: A survey was conducted in a sample of individuals residing in 
Europe and aged 15 to 24. To ensure representativeness, the quota method was 
applied considering age, sex, residence location and occupational status of the 
reference person. Study participants were asked to complete a specifically devel-
oped questionnaire online, on two occasions separated by 6 months (not reported 
here). results: A total of 10 521 questionnaires were completed yielding an self-
reported average prevalence of acne of 57.8% in European adolescents. However, 
there were variations across countries, prevalence rates ranged from 42.2% in Poland 
to 73.5% in Czech Republic and Slovakia. Results from a multivariate regression 
demonstrated that heredity is a risk factor for developing acne whereas age appears 
to be protective. Indeed, in all selected countries, a decrease in the prevalence of 
acne associated with age was observed. Highest rates were reported in the age group 
15-17 and lowest in the age group 21-24. Among the lifestyle factors investigated, 
only tobacco and chocolate consumption were associated with acne. Indeed, the 
former seems to prevent acne whereas the latter was associated with a higher prob-
ability of experiencing the condition. ConClusions: The self-declared prevalence 
of acne is relatively high in European adolescents even if there are variations across 
countries. Heredity is the main identified risk factor for developing acne whereas 
age is negatively associated with the prevalence of this condition.
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objeCtives: The incidence of malignant melanoma has increased in the recent years 
and the role of ultraviolet radiation (UV) in the disease process is well established. 
Indeed, epidemiological data supported that sun exposure and, more particularly 
sunburns during childhood are associated with a higher risk of developing melanoma. 
The present study aims at evaluating sun exposure habits in the Mexican population 
and at assessing, in this population, the knowledge of risks associated with such expo-
sure. Methods: A total of 400 dermatologists practicing in the 11 most important 
cities of Mexico have been selected to participate in the study. Over a period of one 
week, each year from 2011 to 2014, they submitted questionnaires to every consulting 
patient whichever the reason for the consultation. These self-administered question-
naires were completed by the patients and aim at collecting data on sun exposure 
and prevention habits in the population as well as at evaluating knowledge about 
risks associated with sun exposure. results: A total of 11841 questionnaires were 
completed. The mean age of the study population was 49.3 years and respondents 
were predominantly women (sex ratio 2:1). The majority of individuals reported usu-
ally staying in the sun less than 2 hours a day but exposed themselves between 11 am 
and 4pm. However, most people reported using sunscreen when going to the beach 
and protecting themselves with tee-shirts and/or sunglasses. Sunscreen was pre-
dominantly bought in pharmacies but most people applied it only once day. Regarding 
knowledge on the risks associated with sun exposure, the study highlighted many 
gaps, particularly concerning differences between UVA and UVB and their health 
consequences. ConClusions: Enhancing knowledge about the risks associated with 
sun exposure is essential because a better und-erstanding of these risks is key for 
modifying people habits and improving outcomes.
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objeCtives: A 3-year budget-impact model (BIM) was developed to estimate the 
impact on the Italian health care budget of introducing omalizumab for the treat-
ment of patients with chronic spontaneous urticaria (CSU) with inadequate response 
to H1-antihistamines (licensed dose). Methods: The model considered patients with 
CSU aged ≥ 12 years. The BIM was developed from the perspective of the Italian National 
Health Service (NHS). Only direct medical costs were considered: drug costs (omali-
zumab 300mg and H1-antihistamines), drug-related costs (administration, screening 
and monitoring) and disease-related costs (physician, emergency department and hos-
pitalisation). Omalizumab 300mg uptake was assumed to be 10.9% in the first year, 
17.5% in the second year and 28.6% in the third year (only treatments that would be 
substituted for omalizumab were included in the market treatment shares). Ex-factory 
prices (included all discounts) and National Tariffs were considered to estimate costs of 
drug and medical resource used, respectively. Costs were assessed in Euros (2015 val-
ues). results: The total number of patients treated in the first year was estimated to 
be 27,490, with 2,996 of those treated with omalizumab, increasing to a total of approxi-
mately 27,708 in the third year, with 7,925 receiving omalizumab. Considering only drug 
costs, the incremental budget impact of introducing omalizumab 300mg to the current 
market share was estimated to be € 4.4 million in the first year, increasing to € 11.7 mil-
lion in the third year. Considering total direct medical costs, it was possible to show 
that part of the incremental drug costs of introducing omalizumab 300mg was offset 
